Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Pazopanib Hydrochloride

FDA-approved product (tablet, oral), marketed as Pazopanib Hydrochloride, Votrient.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Pazopanib Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Chromophobe renal cell carcinoma
  • Clear cell renal carcinoma
  • Collecting duct carcinoma
  • Papillary renal cell carcinoma
  • Renal cell carcinoma
  • Sarcoma
  • Soft tissue sarcoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other protein kinase inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA38.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli33.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae29.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis67.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Pazopanib Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Pazopanib Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer

    NCT01236547 · start 2010-10-28

    Registered record
    Registry ID
    NCT01236547
    Conditions
    Thyroid Gland Anaplastic Carcinoma
    Interventions
    Intensity-Modulated Radiation Therapy; Paclitaxel; Pazopanib Hydrochloride; Placebo Administration
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-10-28
    Completion
    2022-05-20
    Enrolment
    123

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThyroid Gland Anaplastic Carcinoma
    InterventionIntensity-Modulated Radiation Therapy; Paclitaxel; Pazopanib Hydrochloride; Placebo Administration
    PhasePhase 2
    Registry statusCompleted

  • Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer

    NCT01158521 · start 2010-06

    Registered record
    Registry ID
    NCT01158521
    Conditions
    Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer
    Interventions
    pazopanib hydrochloride; therapeutic conventional surgery
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-06
    Completion
    2016-01
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionClear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer
    Interventionpazopanib hydrochloride; therapeutic conventional surgery
    PhasePhase 2
    Registry statusCompleted

  • Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer

    NCT01027598 · start 2010-01

    Registered record
    Registry ID
    NCT01027598
    Conditions
    Non Small Cell Lung Cancer
    Interventions
    Pazopanib; Erlotinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-01
    Completion
    2014-06
    Enrolment
    202

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon Small Cell Lung Cancer
    InterventionPazopanib; Erlotinib
    PhasePhase 2
    Registry statusCompleted

  • Study of Pazopanib and Ixabepilone in Patients With Solid Tumors

    NCT01012362 · start 2009-12

    Registered record
    Registry ID
    NCT01012362
    Conditions
    Breast Cancer; Lung Cancer; Colon Cancer; Pancreatic Cancer; Head and Neck Cancer; Kidney Cancer; Sarcoma; Hepatocellular Cancer
    Interventions
    Pazopanib; Ixabepilone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2009-12
    Completion
    2013-02
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Lung Cancer; Colon Cancer; Pancreatic Cancer +4 more
    InterventionPazopanib; Ixabepilone
    PhasePhase 1
    Registry statusTerminated

  • Pazopanib Hydrochloride in Treating Patients With Metastatic Urethral Cancer or Bladder Cancer That Has Relapsed or Not Responded to Treatment

    NCT01031875 · start 2009-12

    Registered record
    Registry ID
    NCT01031875
    Conditions
    Bladder Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer
    Interventions
    pazopanib hydrochloride; fludeoxyglucose F 18
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-12
    Completion
    2012-08
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBladder Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer
    Interventionpazopanib hydrochloride; fludeoxyglucose F 18
    PhasePhase 2
    Registry statusCompleted

  • Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment

    NCT00929903 · start 2009-06

    Registered record
    Registry ID
    NCT00929903
    Conditions
    Childhood Central Nervous System Choriocarcinoma; Childhood Central Nervous System Embryonal Tumor; Childhood Central Nervous System Germ Cell Tumor; Childhood Central Nervous System Germinoma; Childhood Central Nervous System Mixed Germ Cell Tumor; Childhood Central Nervous System Teratoma; Childhood Central Nervous System Yolk Sac Tumor; Metastatic Childhood Soft Tissue Sarcoma; Recurrent Childhood Brain Stem Glioma; Recurrent Childhood Central Nervous System Embryonal Tumor; Recurrent Childhood Soft Tissue Sarcoma; Recurrent Childhood Visual Pathway Glioma; Unspecified Childhood Solid Tumor, Protocol Specific
    Interventions
    pazopanib hydrochloride; pharmacological study
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-06
    Completion
    Not recorded
    Enrolment
    55

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChildhood Central Nervous System Choriocarcinoma; Childhood Central Nervous System Embryonal Tumor; Childhood Central Nervous System Germ Cell Tumor; Childhood Central Nervous System Germinoma +9 more
    Interventionpazopanib hydrochloride; pharmacological study
    PhasePhase 1
    Registry statusCompleted

  • Pazopanib Hydrochloride in Treating Patients With Metastatic Melanoma That Cannot be Removed by Surgery

    NCT00861913 · start 2009-04-03

    Registered record
    Registry ID
    NCT00861913
    Conditions
    Recurrent Melanoma; Stage IV Cutaneous Melanoma AJCC v6 and v7
    Interventions
    Laboratory Biomarker Analysis; Pazopanib Hydrochloride; Pharmacological Study
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-04-03
    Completion
    2014-01-16
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Melanoma; Stage IV Cutaneous Melanoma AJCC v6 and v7
    InterventionLaboratory Biomarker Analysis; Pazopanib Hydrochloride; Pharmacological Study
    PhasePhase 2
    Registry statusCompleted

  • Pazopanib in Treating Patients With Metastatic Urothelial Cancer

    NCT00471536 · start 2008-08

    Registered record
    Registry ID
    NCT00471536
    Conditions
    Distal Urethral Cancer; Proximal Urethral Cancer; Recurrent Bladder Cancer; Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter; Recurrent Urethral Cancer; Stage IV Bladder Cancer; Transitional Cell Carcinoma of the Bladder; Urethral Cancer Associated With Invasive Bladder Cancer
    Interventions
    pazopanib hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-08
    Completion
    2013-12
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDistal Urethral Cancer; Proximal Urethral Cancer; Recurrent Bladder Cancer; Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter +4 more
    Interventionpazopanib hydrochloride
    PhasePhase 2
    Registry statusCompleted

  • Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer

    NCT00625846 · start 2008-02-22

    Registered record
    Registry ID
    NCT00625846
    Conditions
    Recurrent Thyroid Gland Carcinoma; Stage III Differentiated Thyroid Gland Carcinoma AJCC v7; Stage III Thyroid Gland Medullary Carcinoma AJCC v7; Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7; Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v7; Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7; Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7; Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v7; Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7; Stage IVC Differentiated Thyroid Gland Carcinoma AJCC v7; Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v7; Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7; Thyroid Gland Anaplastic Carcinoma
    Interventions
    Laboratory Biomarker Analysis; Pazopanib Hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-02-22
    Completion
    2019-08-13
    Enrolment
    152

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Thyroid Gland Carcinoma; Stage III Differentiated Thyroid Gland Carcinoma AJCC v7; Stage III Thyroid Gland Medullary Carcinoma AJCC v7; Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7 +9 more
    InterventionLaboratory Biomarker Analysis; Pazopanib Hydrochloride
    PhasePhase 2
    Registry statusCompleted

  • A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid Tumors

    NCT00619424 · start 2007-11-15

    Registered record
    Registry ID
    NCT00619424
    Conditions
    Lung Cancer, Non-Small Cell
    Interventions
    pazopanib; erlotinib; pemetrexed
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2007-11-15
    Completion
    2009-09-04
    Enrolment
    58

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Cancer, Non-Small Cell
    Interventionpazopanib; erlotinib; pemetrexed
    PhasePhase 1
    Registry statusCompleted

  • Pazopanib Hydrochloride With or Without Bicalutamide in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

    NCT00486642 · start 2007-09

    Registered record
    Registry ID
    NCT00486642
    Conditions
    Hormone-Resistant Prostate Cancer; Recurrent Prostate Carcinoma
    Interventions
    Bicalutamide; Laboratory Biomarker Analysis; Pazopanib Hydrochloride; Pharmacological Study
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-09
    Completion
    2015-09
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHormone-Resistant Prostate Cancer; Recurrent Prostate Carcinoma
    InterventionBicalutamide; Laboratory Biomarker Analysis; Pazopanib Hydrochloride; Pharmacological Study
    PhasePhase 2
    Registry statusCompleted

  • Pazopanib Hydrochloride in Treating Patients With Stage IV or Recurrent Nasopharyngeal Cancer

    NCT00454142 · start 2007-08

    Registered record
    Registry ID
    NCT00454142
    Conditions
    Recurrent Lymphoepithelioma of the Nasopharynx; Recurrent Squamous Cell Carcinoma of the Nasopharynx; Stage IV Lymphoepithelioma of the Nasopharynx; Stage IV Squamous Cell Carcinoma of the Nasopharynx
    Interventions
    pazopanib hydrochloride; pharmacological study; computed tomography
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-08
    Completion
    2010-08
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Lymphoepithelioma of the Nasopharynx; Recurrent Squamous Cell Carcinoma of the Nasopharynx; Stage IV Lymphoepithelioma of the Nasopharynx; Stage IV Squamous Cell Carcinoma of the Nasopharynx
    Interventionpazopanib hydrochloride; pharmacological study; computed tomography
    PhasePhase 2
    Registry statusCompleted

  • Study of Pazopanib, Irinotecan and Cetuximab in Combination to Treat 2nd Line Metastatic Colorectal Cancer

    NCT00540943 · start 2007-07-13

    Registered record
    Registry ID
    NCT00540943
    Conditions
    Neoplasms, Colorectal
    Interventions
    Pazopanib; Cetuximab; Irinotecan
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2007-07-13
    Completion
    2010-05-03
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeoplasms, Colorectal
    InterventionPazopanib; Cetuximab; Irinotecan
    PhasePhase 1
    Registry statusCompleted

  • Pazopanib in Treating Patients With Recurrent or Metastatic Breast Cancer

    NCT00509587 · start 2007-06

    Registered record
    Registry ID
    NCT00509587
    Conditions
    Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer
    Interventions
    pazopanib hydrochloride; pharmacological study; laboratory biomarker analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-06
    Completion
    2013-08
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer
    Interventionpazopanib hydrochloride; pharmacological study; laboratory biomarker analysis
    PhasePhase 2
    Registry statusCompleted

  • Pazopanib in Treating Patients With Recurrent Glioblastoma

    NCT00459381 · start 2007-05

    Registered record
    Registry ID
    NCT00459381
    Conditions
    Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Recurrent Adult Brain Tumor
    Interventions
    pazopanib hydrochloride; laboratory biomarker analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-05
    Completion
    2008-12
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Recurrent Adult Brain Tumor
    Interventionpazopanib hydrochloride; laboratory biomarker analysis
    PhasePhase 2
    Registry statusCompleted